Unknown

Dataset Information

0

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report.


ABSTRACT: Brain metastasis (BM) has been universally recognized as a poor prognostic factor in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown efficacy in treating BM with an EGFR mutation. This paper reports a case of BM patient with EGFR-mutated NSCLC. According to the findings, a complete remission (CR) of the BM was achieved by icotinib treatment without conducting a radiotherapy, which was followed by a resection of the primary lung cancer lesion and lymph nodes. After one-year follow-up, the disease progressed to liver metastasis and liver lesion biopsy showed a T790M mutation. The patient responded well to the combination treatment of AZD9291 and icotinib after the failure of transcatheter arterial chemoembolization (TACE). This case report suggests that icotinib has a sustainable anticancer response to BM and the combination with icotinib and AZD9291 is effective for liver metastasis with T790M.

SUBMITTER: Wang T 

PROVIDER: S-EPMC5329790 | BioStudies | 2016-01-01T00:00:00Z

SECONDARY ACCESSION(S): NCT01724801

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC6943154 | BioStudies
2017-01-01 | S-EPMC5362911 | BioStudies
2015-01-01 | S-EPMC4608803 | BioStudies
2014-01-01 | S-EPMC4315625 | BioStudies
2020-01-01 | S-EPMC6993327 | BioStudies
2020-01-01 | S-EPMC7097919 | BioStudies
2018-01-01 | S-EPMC5895014 | BioStudies
2019-01-01 | S-EPMC6625885 | BioStudies
2019-01-01 | S-EPMC6400687 | BioStudies
2014-01-01 | S-EPMC4023939 | BioStudies